Report a possible side effect

At GSK we take the safety of our patients very seriously. We know that side effects can happen, but it is not always possible to predict who will experience them. We continuously monitor the safety of our products and by hearing about your experiences we can offer the best possible advice to people using our products.

How to report a possible side effect?

To help us process your information quickly and effectively, please report as much relevant information as possible.  At a minimum you will need to provide the following:

  1. The initials of the person who experienced the possible side effect and/or other identifiers, such as gender, date of birth
  2. The contact information of the person reporting the issue
  3. A description of the possible side effect, such as the signs and symptoms experienced, date the possible side effect started and the result of the possible side effect
  4. The name of the GSK product

Our Privacy Notice outlines how we handle the processing of personal information when dealing with your enquiry, complaint or adverse event report.

For contact details and to report a possible side effect, please select your home market from the list below.

Algeria

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +21321989630

Email address: pharmacovigilance.na@gsk.com

Bahrain

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: gulf.safety@gsk.com

Benin

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

 

Burundi

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Cameroon

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Central African Republic 

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Chad

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Congo Brazzaville 

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Cote d’Ivoire

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Democratic Republic of the Congo

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Djibouti

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Egypt

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +20 (2) 26185150

Email address: ae.egypt@gsk.com

Ethiopia

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Gabon

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Ghana

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Guinea

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Gulf & Near East

Telephone number:

Gulf Tel: +97144037100
Near East: +9611449646

Email address:

Gulf: gulf.safety@gsk.com
Near East: NE.Safety@gsk.com

Iran

To report a possible side effect:

Email address: pm.safety@gsk.com

Iraq

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Israel

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +97239297100

Email address: il.safety@gsk.com

Jordan

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Kazakhstan

To report a possible side effect:

Telephone number: +7 727 313 1207

Email address: kz.safety@gsk.com 

Kenya

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

 

Kuwait

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: gulf.safety@gsk.com

Lebanon

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Liberia

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

 

Libya

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Mali

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Morroco

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +212 5 22 48 00 02

Email address: pharmacovigilance.na@gsk.com

Niger

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Nigeria

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

 

Oman

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: gulf.safety@gsk.com

Qatar

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: gulf.safety@gsk.com

Rwanda

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Saudi Arabia

Telephone number:

+966569049882

Email address:

saudi.safety@gsk.com

Senegal

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Sierra Leone

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

South Africa

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +27 10 300 1000

Email address: aereporting.za@gsk.com

Southern Africa

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Sudan North

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email Address: pm.Safety@gsk.com

Syria

To report a possible side effect:

Email address: pm.safety@gsk.com

Tanzania

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Togo

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Tunisia

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Uganda

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

United Arab Emirates

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: gulf.safety@gsk.com

Western & Central Africa

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Yemen

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Zambia

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Zimbabwe

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Argentina

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: 0800 220 4752

Email address: bua-farmacovigilancia-rx@gsk.com

Bolivia and Paraguay

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +541147258900

Email address: Bua-Farmacovigilancia-Rx@gsk.com

Brazil

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +08007012233

Email address: farmacovigilancia@gsk.com

Canada

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +18003877374

Email address: drugsurv.a.ca@gsk.com

Chile

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +56223829000 

Email address: farmacovigilancia.chile@gsk.com

 

 

Colombia

Telephone number:

+18000118686

Email address:

programa.dirmedica@gsk.com

Costa Rica

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +(506)40554242

Email address: fv.aecaricam@gsk.com

Dominican-Republic

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +18299566335

Email address: fv.aecaricam@gsk.com

 

Ecuador

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +59322994700 Ext. 5

Email address: farmacovigilancia.ecuador@gsk.com

El-Salvador

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +(503)21367801

Email address: fv.aecaricam@gsk.com

Guatemala

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +(502)23761930

Email address: fv.aecaricam@gsk.com

Honduras

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +(504)25401638

Email address: fv.aecaricam@gsk.com

Jamaica

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +18766302074

Email address: fv.aecaricam@gsk.com

Mexico

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number (toll free): 800 276 9263

Email address: farmacovigilancia.mx@gsk.com

Nicaragua

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +(505) 67795256

Email address: fv.aecaricam@gsk.com

Panama

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +(507)8336768

Email address: fv.aecaricam@gsk.com 

Peru

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +5112119700

Email address: farmacovigilancia.peru@gsk.com

Trinidad and Tobago

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +18682245759

Email address: fv.aecaricam@gsk.com

Uruguay

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +59824198333 

Email address: uy.farmacovigilancia@gsk.com

USA

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Tel: +1 888 825 5249

Email: WW.GSKAEReportingUS@gsk.com

Venezuela

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +58 (0800) 8987987

Email address: ven.farmacovigilancia@gsk.com

Afghanistan

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.Safety@gsk.com

Armenia

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +74957778900

Email address: ru.safety@gsk.com

Australia

To report a possible side effect:

Online: Adverse event reporting form

Tel: 1800 033 109 or +61 3 9413 7200

 

 

 

Azerbaijan

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Bangladesh

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: oax70065@gsk.com

Cambodia

To report a possible side effect:

Email address: pm.safety@gsk.com

China (Mainland)

Telephone number:

+868008203383

+864001833383

Email address:

oax32250@gsk.com

Hong Kong and Macau

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +85231898989 (Hong Kong) or +853 28715569 (Macau)

Email address: HKAdverseEvent@gsk.com

India

To report a possible side effect:

Toll free number: +1800222203

Telephone number: +912224959595

Mobile number: +91-8657549542

Email: india.pharmacovigilance@gsk.com

Indonesia

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +622125532350

Email address: yqq68540@gsk.com

 

Korea

Telephone number

+82809014100

E-mail address

kr-medical.drug-safety@gsk.com

Kyrgyzstan

To report a possible side effect: 

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +74957778900

Email address: ru.safety@gsk.com

Laos

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Malaysia & Brunei

Online: Patient safety reporting form (Preferred method of contact)

Email address: drugsafetyinfo.my@gsk.com

Mongolia

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Myanmar

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

New Zealand

To report a possible side effect:

Online: Adverse event reporting form

Tel: 0800 808 500 or +64 9 367 2900

 

 

Pakistan

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +9221111475725 EXT 7 OR 8

Email address: pk_pharmasafety@gsk.com

Philippines

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +632 8892 0761

Email address: ph.safety@gsk.com

 

Singapore

Online: Patient safety reporting form (Preferred method of contact)

Email address: sg.drugsafety@gsk.com

Sri-Lanka

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Taiwan

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +886223126836

Email address: oax40892@gsk.com

Tajikistan

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Thailand

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: safety_th@gsk.com

Turkmenistan

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Uzbekistan

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Vietnam

Telephone number:

Tel: +84 28 3824 8744
Mob: +84 96390 5235

Email address:

antoanthuoc.vn@gsk.com

Albania

Telephone number:

+35542232855 +355692044295

Email address:

s.riza@megapharm.al

e.arapi@megapharm.al

Website address:

www.megapharm.al

 

Kosovo

Telephone number:

+38338600776

Austria

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +431970750

Email address: arzneimittelsicherheit@gsk.com

Belarus

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +74957778900

Email address: by.safety@gsk.com

 

Belgium

Telephone number:

+3210855200

Email address:

be.medinfo@gsk.com

Bosnia & Herzegovina

Telephone number:

+387(0)33774300

Email address:

pv@elpharma.ba

Bulgaria

Telephone number:

+35980018205

Email address:

safety-bg@gsk.com

Croatia

Telephone number:

+385800787089

Email address:

cro.nuspojave@gsk.com

Cyprus

Telephone number:

+35780070017

Email address:

cy.safety@gsk.com

Czech-Republic

Email address:

cz.safety@gsk.com

Denmark

Online: Patient safety reporting form

Telephone number: +4536359100

Email address: dk-safety@gsk.com

Estonia

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +3728002640

Email address: estoniansafety@gsk.com   

Finland

Online: Patient safety reporting form

Telephone number: +35810303030

France

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +33139178444

Email address: diam@gsk.com

Georgia

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Germany

Email address: Drug-Safety.Germany@gsk.com

 

Greece

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +302106882100

Email address: gr.pharmacovigilance@gsk.com

Hungary

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +3680088309 

Email address: Hungary.PH_Safety@gsk.com  

Iceland

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +4536359100

Email address: dk-safety@gsk.com

Ireland

To report a possible side effect:

Online: Patient safety reporting form

Tel: 1800 244 255

Email: Ireland.Drugsurveillance@gsk.com

 

Italy

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +390457748005

Email address: drugsurveillance-italy@gsk.com

 

Latvia

Telephone number:

+37180205045

Email address:

quz52333@gsk.com

Lithuania

Telephone number:

+37080000334

Email address:

safety.lt@gsk.com

Luxembourg

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +3210855200

Email address: be.medinfo@gsk.com

 

Malta

Telephone number:

+35680065004

Email address:

mt.safety@gsk.com

 

 

Moldova

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: pm.safety@gsk.com

Montenegro

Telephone number:

+382(0)77272735

Email address:

pv@elpharma.me

Netherlands

To report a possible side effect:

Telephone number: +31332081100

Email address: nl.bijwerking@gsk.com

North Macedonia

Telephone number:

+389(0)22786074

+389(0)22700573

Email address:

pharmacovigilance@elpharma.com.mk

Norway

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +4722702000

Email address: no.safety@gsk.com

Poland

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +48225769000

Email address: uyz84328@gsk.com

Portugal

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +351214129500

Email address: LIS.Nucleo-Farmacovigilancia@gsk.com

Romania

Telephone number:

+40 800672524

Email address:

farmacovigilenta.romania@gsk.com

 

Russia

To report a possible side effect:

Telephone number: +74957778900

Email address: ru.safety@gsk.com

Serbia

Email address:

drugsafety@elpharma.com

Slovakia

Telephone number:

+421800500589

Email address:

sk-safety@gsk.com

Telephone number:

+38680688869

Email address:

LJU.farmakovigilanca@gsk.com

 

 

Spain

Telephone number:

(+34)900202700

Email address:

unidad.farmacovigilancia@gsk.com

Sweden

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +4686389300

Email address: safetysweden@gsk.com

Switzerland

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Telephone number: +41318622111

Email address: pv.swiss@gsk.com

Turkey

Telephone number:

+902124445475

Email address:

IST_TR_safety@gsk.com

Ukraine

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Email address: oax70065@gsk.com

United Kingdom

To report a possible side effect:

Online: Patient safety reporting form (Preferred method of contact)

Tel: 0800 221 441

Email: uksafety@gsk.com